Evidence map›Paper›PMID 42167806›Full record

Observational studyJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.

Nika Guberina, Madeleine J Karpinski, Maja Guberina, Sebastian Hoberück, Matthias Miederer, Tobias Hölscher, Isabel Rauscher, Matthias Eiber, Andrew Nguyen, Lela Theus and 28 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06320223 (PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06320223 recruitingnot on this map

PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer

Typeobservational_patient_registrySponsorUniversity Hospital, EssenRan2024 to 2035Enrolled10,000ConditionsProstate Cancer, PET/CT, Survivorship, PSMA
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Nika GuberinaDepartment of Radiotherapy, West German Cancer Center, NCT, University Hospital Essen, Essen, Germany; nika.guberina@uk-essen.de.
Madeleine J KarpinskiDKTK, Partner Site University Hospital Essen, Germany.
Maja GuberinaDepartment of Radiotherapy, West German Cancer Center, NCT, University Hospital Essen, Essen, Germany.
Sebastian HoberückDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Matthias MiedererDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Tobias HölscherDepartment of Radiotherapy and Radiation Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany and.
Isabel RauscherDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Munich, Germany.
Matthias EiberDepartment of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Munich, Germany.
Andrew NguyenAhmanson Translational Theranostics Division, Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine at UCLA, Los Angeles, California.
Lela TheusAhmanson Translational Theranostics Division, Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine at UCLA, Los Angeles, California.
Matteo BaucknehtIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Helen ScholtissekNuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Kambiz RahbarDepartment of Nuclear Medicine, University Hospital Münster and West German Cancer Center, Münster, Germany.
Jonathan MikschDepartment of Radiology, Ulm University Hospital, Ulm, Germany.
Daniele Antonio PizzutoDirezione Scientifica GSTeP Radiopharmacy, Department of Radiology and Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Karolien GoffinNuclear Medicine, University Hospitals Leuven, and Nuclear Medicine & Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Caner CivanDKTK, Partner Site University Hospital Essen, Germany.
Shima F ReinwandDKTK, Partner Site University Hospital Essen, Germany.
Andreas StangInstitute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany.
Jens KleesiekInstitute for AI in Medicine, University Medicine Essen, Essen, Germany.
Anja Merkel-JensInstitute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany.
Lale UmutluDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Alfonso SantangeloUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, VitaSalute San Raffaele University, Milan, Italy.
Timo F W SoeterikDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Stephan Beintner-SkawranDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Andrej VondrakIZOTOPCENTRUM, s.r.o, Nuclear Medicine Department, Nitra, Slovakia.
Anders BjartellDepartment of Urology, Skåne University Hospital, Malmö, Sweden.
Laura EvangelistaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Sazan RasulDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Marcin MiszczykDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Adrien HolzgreveAhmanson Translational Theranostics Division, Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine at UCLA, Los Angeles, California.
Gabriel T SheikhDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Andrea Di GiorgioNuclear Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Andrea FarolfiNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy; and.
Ken HerrmannDKTK, Partner Site University Hospital Essen, Germany.
Boris HadaschikDKTK, Partner Site University Hospital Essen, Germany.
Wolfgang P FendlerDKTK, Partner Site University Hospital Essen, Germany.
Martin StuschkeDepartment of Radiotherapy, West German Cancer Center, NCT, University Hospital Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of salvage radiotherapy (SRT) on overall survival (OS) in patients experiencing biochemical recurrence (BCR) of prostate cancer remains an area of active investigation. The international multicenter PROMISE registry provides a valuable dataset to explore the association between SRT and long-term clinical outcomes in this patient population (NCT06320223).

Indexed as

Prostatic NeoplasmsRegistriesSalvage TherapyAgedHumansMaleMiddle AgedNeoplasm Recurrence, LocalProstate-Specific AntigenRecurrenceSurvival AnalysisTreatment OutcomeProstate-Specific Antigenbiochemical recurrencemolecular imagingoverall survivalprostate cancersalvage radiotherapy

Identifiers

PMID42167806
PMCPMC13435546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.